Can Hydrogen Water Enhance Oxygen Saturation in Patients with Chronic Lung Disease? A Non-Randomized, Observational Pilot Study

Abstract

Background: Recently, chronic lung diseases have been found to be associated with marked inflammation and oxidative stress, which leads to fibrosis in the lungs and chronic respiratory failure. This study aims to determine if hydrogen-rich water (HRW) can enhance oxygen saturation among patients with chronic lung diseases. Methods: Ten patients with chronic lung diseases due to COPD (n = 7), bronchial asthma (n = 2), and tuberculosis of the lung (n = 1) with oxygen saturation of 90–95% were provided high-concentration (>5 mM) HRW using H2-producing tablets for 4 weeks. Oxygen saturation was measured via oximeter and blood pressure via digital automatic BP recorder. Results: HRW administration was associated with a significant increase in oxygen saturation (SpO2) and decrease in TBARS, MDA, and diene conjugates, with an increase in vitamin E and nitrite levels, compared to baseline levels. Physical training carried out after HRW therapy appeared to increase exercise tolerance and decrease hypoxia, as well as delay the need for oxygen therapy. Conclusion: Treatment with HRW in patients with hypoxia from chronic lung diseases may decrease oxidative stress and improve oxygen saturation in some patients. HRW therapy may also provide increased exercise tolerance in patients with chronic hypoxia, but further research is needed.

Mitochondria as a key target of molecular hydrogen

“…Митохондрии как ключевая мишень воздействия молекулярного водорода острым воспалением заболевания [2][3][4][5]. За полтора десятилетия активных исследований достаточная без опасность водорода продемонстрирована на лабора торных животных, появляется также все больше обна деживающих предварительных клинических исследо ваний на небольших выборках пациентов, страдающих различными заболеваниями [6][7][8][9][10][11]. Дополнительное внимание к молекулярному водороду в последние не сколько лет привлекла также его способность улучшать состояние пациентов с постковидным синдромом [7,12].…”